Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.

Molecular psychiatry - 1 Jul 2015

Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen R C, Dufour R, Poirier J

Abstract excerpt

Several retrospective epidemiological studies report that utilization of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors called statins at mid-life can reduce the risk of developing sporadic Alzheimer's disease (AD) by as much as 70%. Conversely, the administration of these inhibitors in clinically diagnosed subjects with AD confers little or no benefits over time. Here, we investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Apolipoprotein E4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognitive Dysfunction

Share to Hydroxymethylglutaryl CoA Reductases

Share to Kaplan-Meier Estimate

Share to Logistic Models

Share to Sex Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 25023145
DOI: 10.1038/mp.2014.81
PMCID: PMC4318698

Genes

HMGCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.PMID 25023145Read ↗

Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.Semantic proximity Read ↗

Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.Semantic proximity Read ↗

Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese.Semantic proximity Read ↗

Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease.Semantic proximity Read ↗

Lipid lowering and Alzheimer disease risk: A mendelian randomization study.Semantic proximity Read ↗

APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts.Semantic proximity Read ↗

Sex modifies the APOE-related risk of developing Alzheimer disease.Semantic proximity Read ↗

Single‐nucleotide polymorphisms are associated with cognitive decline at Alzheimer's disease conversion within mild cognitive impairment patientsSemantic proximity Read ↗

Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.Semantic proximity Read ↗

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.Semantic proximity Read ↗

DNA Methylation and Tag SNPs of the BDNF Gene in Conversion of Amnestic Mild Cognitive Impairment into Alzheimer's Disease: A Cross-Sectional Cohort Study.Semantic proximity Read ↗

Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.